Tybourne Capital Management (Hk) LTD Lian Bio Transaction History

Tybourne Capital Management (Hk) LTD

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	BUY	$1.33 - $4.6 $126,771 - $438,458	95,317 Added 2.89%	3,398,890 $15.2 Million
Q3 2022 Nov 14, 2022	SELL	$1.87 - $3.0 $19,822 - $31,800	-10,600 Reduced 0.32%	3,303,573 $6.61 Million
Q4 2021 Feb 25, 2022	SELL	$6.14 - $16.2 $6 - $16	-1 Reduced -0.0%	3,314,173 $20.4 Million
Q4 2021 Jan 26, 2022	BUY	$6.14 - $16.2 $20.3 Million - $53.7 Million	3,314,174 New	3,314,174 $20.4 Million

1.1M

Ticker LIAN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 108,354,000
Market Cap $31.4M
Description
LianBio, a biopharmaceutical company, engages in developing and commercializing medicines for cardiovascular, oncology, respiratory, opthalmology, and inflammatory diseases in China and other Asian countries. The company develops mavacamten for the treatment of obstructive and non-obstructive hypertrophic cardiomyopathy, and heart failure with p...

Get notified when there are updates to the investment portfolio of Tybourne Capital Management (Hk) LTD, based on Form 13F filings with the SEC.

Stay updated on Tybourne Capital Management (Hk) LTD with notifications on news.